Early Phase 1 Peripheral Arterial Disease Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People who have a brain lesion (an abnormal area in the brain) and are already scheduled to have it surgically removed as part of their normal medical care — this includes people who have previously had chemotherapy, radiation, or a biopsy to diagnose their condition.
- People aged 18 years or older.
- People whose blood tests and organ function results (including kidney, liver, and blood counts) are considered acceptable for surgery and for receiving the study drug — these tests must have been done within 30 days before starting the study treatment.
- Women who could become pregnant must have a negative pregnancy test within 7 days before receiving the study drug.
- People who are able to understand and sign a consent form, or who have a healthcare decision-maker who can sign on their behalf.
Who may not be able to join:
- People who have had a heart attack, stroke, or uncontrolled heart failure within the 6 months before joining the trial.
- People who have previously had a serious reaction to a monoclonal antibody treatment (a type of targeted therapy drug).
- People who are currently pregnant or breastfeeding.
- People whose heart electrical activity test (ECG) shows a specific irregular reading above a certain threshold (confirm with trial site).
- People who have low magnesium or phosphorus levels in their blood and are experiencing symptoms related to this.
- People who are currently taking certain heart rhythm medications, specifically those known as Class IA drugs (such as quinidine or procainamide) or Class III drugs (such as amiodarone, dofetilide, or sotalol).
- People who have a history of, or signs of, scarring or inflammation in their lungs (such as interstitial pneumonitis or pulmonary fibrosis).
- People who have severe kidney disease or produce no urine.
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Peter Morone, MD, Vanderbilt University Medical Center
Phone: 615-421-4370
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Determine the safety of panitumumab-IRDye800 as an imaging agent in patients undergoing surgery for intracranial lesions.
Can't join this trial?
Data last synced from ClinicalTrials.gov: 22 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.